Using core genes and pathways to stratify rheumatoid arthritis and predict outcomes in Rheumatoid Arthritis

MRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

August 30, 2026
Response Due
Active
Status

Opportunity Overview

Rheumatoid arthritis is a long-term condition in which the immune system attacks the joints. It affects 1 in 100 people in the United Kingdom. This inflammation causes pain and, if uncontrolled, can lead to joint damage and disability. The earlier we can control the inflammation, the better the long-term outcomes. The development of biologic therapies means that we now have more options than ever before to treat rheumatoid arthritis. There are a number of types of these drugs, all affecting different immune pathways to try and reduce inflammation. We have no reliable way of predicting which type of biologic treatment will be most effective for an individual. Currently, selection is done by a process of trial and error with each new drug trialled for a period of time. During this time, if the drug does not work, a person may develop irreversible joint damage which could lead to permanent disability.

The aim of this study is to see whether genetic and protein markers, identified using a blood sample, can be used to predict whether a person with rheumatoid arthritis is likely to respond to a certain treatment and inform us about the likely severity of their disease. These are known as biomarkers. This project will analyse data collected in MATURA (Maximising Therapeutic Utility in Rheumatoid Arthritis), a nationwide consortium of academics, doctors and industry groups developing personalised approaches to treatment of rheumatoid arthritis.

When researching biomarkers of treatment response, it is really important to first establish what we consider a good response to be. One of the methods health professionals use in clinical practice is a scoring system known as the DAS-28 score. This score is made up of four components: number of tender joints, number of swollen joints, the patient global visual analogue score (a self-reported score from 0-100 of a patient's overall health) and CRP (C-reactive protein, a blood test which measures inflammation). Lots of factors can...

This is one of 1,831 active United Kingdom Research Development opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
PublishedAugust 31, 2024
Procurement stageActive solicitation
Response dueAugust 30, 2026
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Rotation year
Title of project: Evaluation of the quantitative accuracy and radiation dosimetry of an advanced pre-clinical multipinhole SPECT/CT theranostic imag
Discerning MCT1s role in chromatin remodelling and metabolomics changes in cancer progression
Leveraging real world data to characterise the long term impact of COVID-19
Bacterial antibiotic resistance: structure, mechanism and inhibition of ABC transporters responsible for drug efflux and cell wall biogenesis.
Characterising the role of TEX12 in centrosome and cilia development
Allogeneic Chondroprogenitor Therapy (Phase II) (ACT2)
Iron and immunity

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.